Research Paper Volume 12, Issue 14 pp 14406—14417
Osthole resensitizes CD133+ hepatocellular carcinoma cells to cisplatin treatment via PTEN/AKT pathway
Figure 1. Cisplatin resistance of CD133+ HCC cells. (A) Purity of sorted CD133+ and CD133- Huh7 and HepG2 cells was tested by flow cytometry. (B) Sensitization of CD133+ and CD133- Huh7 and HepG2 cells to different concentrations of cisplatin (0~30 μM). *P<0.05. (C) IC50 of cisplatin to CD133+ and CD133- Huh7 and HepG2 cells. #P<0.05 vs. CD133- population.